Chris Viehbacher
Biogen appointed Viehbacher CEO to lead recovery after an impending patent cliff.
Viehbacher uniquely combines expertise in managing a multibillion-dollar global pharma firm with a strong commitment to innovation.
By skillfully steering M&A, refocusing R&D, and enforcing strict cost discipline, Viehbacher is positioned to drive Biogen’s sustainable growth.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.